ABIVAX Société Anonyme (AAVXF)
- Previous Close
0.00 - Open
15.00 - Bid 9.85 x 40000
- Ask 11.06 x 40700
- Day's Range
15.15 - 15.15 - 52 Week Range
10.19 - 15.15 - Volume
5,000 - Avg. Volume
0 - Market Cap (intraday)
695.241M - Beta (5Y Monthly) 1.45
- PE Ratio (TTM)
-- - EPS (TTM)
-3.70 - Earnings Date Nov 7, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.
www.abivax.comRecent News: AAVXF
View MorePerformance Overview: AAVXF
Trailing total returns as of 11/1/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AAVXF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AAVXF
View MoreValuation Measures
Market Cap
658.60M
Enterprise Value
435.42M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.29
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-46.69%
Return on Equity (ttm)
-171.46%
Revenue (ttm)
9.03M
Net Income Avi to Common (ttm)
-177.42M
Diluted EPS (ttm)
-3.70
Balance Sheet and Cash Flow
Total Cash (mrq)
222.32M
Total Debt/Equity (mrq)
89.64%
Levered Free Cash Flow (ttm)
-89.3M